The role provides strategic statistical leadership and oversight across development planning, regulatory interactions, and HTA/commercial evaluations for Gilead's oncology assets.
Base: $261,375.00 - $338,250.00 (Bay Area); $237,575.00 - $307,450.00 (Other US Locations); Bonus/Equity: Discretionary annual bonus and stock-based long-term incentives; Benefits: Medical, dental, vision, life insurance, and paid time off
Must-have
Nice-to-have
Not specified